This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further awa...
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s re...
The data drops provide more evidence that rocatinlimab improves outcomes in atop...
Boston Scientific led a $175 million funding round for 4C Medical, which is taki...
Nasdaq plans to roll out 24-hour trading for U.S. companies in a move designed t...
The National Institutes of Health unveiled a plan on March 6 to move the peer re...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, wo...
In defiance of federal orders, the National Institutes of Health is still termin...
Arcturus believes it’s “highly unlikely” it will lose the government funding for...
The newest executive to join the ranks at Pfizer is ten-year Johnson & Johnson v...
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular...
This week on "The Top Line," we dig into several of the biggest private funding ...
Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue ...
One of Merck KGaA’s leading immunology assets has flunked the latest part of a p...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils...
Atea Pharmaceuticals has laid off a quarter of its workforce so far this year as...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, ...
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora repo...
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora repo...
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils...
As always, if you know of layoffs occurring at a biotech, please reach out to th...